SEC 13F Intelligence

Managers / Q3 2023 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
Under review
reported total failed a data-quality check
Positions
73
Filings on Record
27
2019–present window
Filed
Nov 14, 2023
original filing

Summary

Compared with Q2 2023, the fund opened 5 new positions and exited 11.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 80.1%ADR: 9.4%Other: 8.5%ETP: 1.9%Equity WRT: 0.0%
  • Common Stock · 80.1% · $1.5B
  • ADR · 9.4% · $177M
  • Other · 8.5% · $159M
  • ETP · 1.9% · $37M
  • Equity WRT · 0.0% · $29,414

Quarter-over-Quarter Changes full breakdown →

vs Q2 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SPDR Ser TrNEW+500.0K500.0K+$37M$37M
IMVTImmunovant IncNEW+750.0K750.0K+$29M$29M
ABOSAcumen Pharmaceuticals IncNEW+2.21M2.21M+$9M$9M
KODKodiak Sciences IncNEW+600.0K600.0K+$1M$1M
Verrica Pharmaceuticals IncNEW+167.0K167.0K+$648,620$648,620
Prothena Corp PLCADDED+325.0K625.0K+$30M$30M
Mersana Therapeutics IncADDED+1.00M2.00M+$3M$3M
RETAEURReata Pharmaceuticals IncSOLD OUT−1.43M0−$145,803$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2023

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MRTXEURMirati Therapeutics Inchistory →Com7.42%$139M3.20M
2RVMDRevolution Medicines Inchistory →Com6.90%$130M4.68M
3ONCBeiGene Ltdhistory →Sponsored ADR4.79%$90M500.0K
4TYRATyra Biosciences Inchistory →Com4.73%$89M6.45M
5AKROAkero Therapeutics Inchistory →Com4.51%$85M1.68M
6TNGXTango Therapeutics Inchistory →Com4.27%$80M7.12M
7SWTXUSDSpringworks Therapeutics Inchistory →Com4.21%$79M3.42M
8SRPTSarepta Therapeutics Inchistory →Com3.87%$73M600.0K
9APLSUSDApellis Pharmaceuticals Inchistory →Com3.50%$66M1.73M
10CYTKCytokinetics Inchistory →Com New3.29%$62M2.10M
11IDYAIdeaya Biosciences Inchistory →Com3.16%$59M2.20M
12NUVLNuvalent Inchistory →Com2.96%$56M1.21M
13IMGNEURImmunoGen Inchistory →Com2.50%$47M2.96M
14Merus N VCom2.38%$45M1.90M
15Karuna Therapeutics IncCom2.25%$42M250.0K
16ARGXArgenx SEhistory →Sponsored ADR2.22%$42M85.0K
17LEGNLegend Biotech Corphistory →Sponsored ADS2.15%$40M600.0K
18AMLXAmylyx Pharmaceuticals Inchistory →Com2.03%$38M2.08M
19SPDR Ser TrS&P Biotech1.94%$37M500.0K
20Prothena Corp PLCSHS1.61%$30M625.0K
21RCKTRocket Pharmaceuticals Inchistory →Com1.60%$30M1.47M
22VTYXUSDVentyx Biosciences Inchistory →Com1.57%$30M850.0K
23IMVTImmunovant Inchistory →Com1.53%$29M750.0K
24RCUSArcus Biosciences Inchistory →Com1.53%$29M1.60M
25AM6Amicus Therapeutics Inchistory →Com1.51%$28M2.33M
26AXSMAxsome Therapeutics Inchistory →Com1.49%$28M400.0K
27EX9Exelixis Inchistory →Com1.34%$25M1.15M
28ANABAnaptysBio Inchistory →Com1.24%$23M1.30M
29SG7Sage Therapeutics Inchistory →Com1.20%$23M1.09M
30VKTXViking Therapeutics Inchistory →Com1.18%$22M2.00M
31XENEXenon Pharmaceuticals Inchistory →Com1.09%$20M600.0K
322662247DiTeos Therapeutics Inchistory →Com1.05%$20M1.80M
33PMVPPMV Pharmaceuticals Inchistory →Com1.03%$19M3.16M
34IOVAIovance Biotherapeutics Inchistory →Com0.90%$17M3.71M
35Point Biopharma Global IncCom0.89%$17M2.50M
364XC1Kalvista Pharmaceuticals Inchistory →Com0.85%$16M1.65M
37RLAYRelay Therapeutics Inchistory →Com0.81%$15M1.82M
38MDGLMadrigal Pharmaceuticals Inchistory →Com0.78%$15M100.0K
39DAWNGBXDay One Biopharmaceuticals Ihistory →Com0.78%$15M1.19M
40ORICOric Pharmaceuticals Inchistory →Com0.56%$10M1.73M
41CGEMCullinan Oncology IncCom0.52%$10M1.07M
42NRIXNurix Therapeutics IncCom0.51%$10M1.22M
43ABOSAcumen Pharmaceuticals IncCom0.49%$9M2.21M
44ZNTLZentalis Pharmaceuticals IncCom0.48%$9M450.0K
45Ascendis Pharma A/SSponsored ADR0.47%$9M95.0K
46ELVNEnliven Therapeutics IncCom0.47%$9M646.1K
47PRLDPrelude Therapeutics IncCom0.41%$8M2.50M
48RNAGBPAvidity Biosciences IncCom0.38%$7M1.12M
49GONGeron CorpCom0.34%$6M3.00M
50GOSSGossamer Bio IncCom0.29%$5M6.50M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.